Insilico Medicine Featured in Harvard Business School Case on Rentosertib (IMAGE)

InSilico Medicine

Insilico Medicine Featured in Harvard Business School Case on Rentosertib

Caption

The case describes Rentosertib as the world’s first drug with both an AI-discovered target and an AI-designed molecular structure to enter Phase II human clinical trials, and uses that milestone to explore the real tradeoffs biotechs, and specifically AI-native biotech companies confront as programs move from discovery into clinical development.

Credit

Insilico Medicine

Usage Restrictions

N/A

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.